Our result is supported by a Phase 2 study showing that CHK1 inhibitor use displays a notable anti-tumor activity as a monotherapy in patients with a subtype of recurrent HGSOC with wild-type BRCA. The gene discussed is CHEK1; the disease is neoplasm.